• Home
  • News
  • Contact
Rokote Laboratories Finland receives a second clinical trial authorization for FINVAC COVID-19 vaccine

Rokote Laboratories Finland receives a second clinical trial authorization for FINVAC COVID-19 vaccine

by Okapit | Dec 18, 2025 | Latest news

Rokote Laboratories Finland Oy is proud to announce that we have received Clinical Trial Authorization (CTA) for our second Phase I clinical trial of the intranasal COVID-19 vaccine. The upcoming study, titled:”A Phase 1a, single-blind, randomized comparative...
Terhi Reunama Appointed as Head of Clinical Trial Operations

Terhi Reunama Appointed as Head of Clinical Trial Operations

by Okapit | Nov 26, 2025 | Latest news

We are pleased to announce the appointment of Terhi Reunama as our new Head of Clinical Trial Operations. Terhi brings nearly 30 years of clinical research experience from both the pharmaceutical industry and CRO organizations. A registered nurse with a Bachelor of...
Our Nasal COVID-19 Vaccine Moves to First Human Trials

Our Nasal COVID-19 Vaccine Moves to First Human Trials

by Okapit | Jan 21, 2025 | Latest news

Rokote Laboratories Finland Oy is starting the first clinical drug trial with its nasal COVID-19 vaccine. The vaccine has been developed and manufactured in Finland, and the study will be conducted at Kuopio University Hospital starting January 21, 2025. The...

Recent Posts

  • Rokote Laboratories Finland receives a second clinical trial authorization for FINVAC COVID-19 vaccine
  • Terhi Reunama Appointed as Head of Clinical Trial Operations
  • Our Nasal COVID-19 Vaccine Moves to First Human Trials
  • Rokote Laboratories Finland Oy Submits First Clinical Trial Application
  • Rokote Laboratories Finland Oy Announces CEO Transition and Future Plans

Recent Comments

No comments to show.

Rokote Laboratories Finland Oy

Company ID: 3155372-4
VAT: FI31553724

  • Follow
Invoicing details